<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01551758</url>
  </required_header>
  <id_info>
    <org_study_id>115151</org_study_id>
    <nct_id>NCT01551758</nct_id>
  </id_info>
  <brief_title>A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A 12-month, Open Label, Randomised, Effectiveness Study to Evaluate Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder Delivered Once Daily Via a Novel Dry Powder Inhaler (NDPI) Compared With the Existing COPD Maintenance Therapy Alone in Subjects With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to compare the effectiveness and safety of Fluticasone
      Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate ((FF), GW685698)/25mcg
      Vilanterol ((VI), GW642444)) delivered once daily via a Novel Dry Powder Inhaler (NDPI)
      compared with the existing COPD maintenance therapy over twelve months in subjects diagnosed
      with COPD. This is a Phase III multi-centre, randomised open label study. Subjects who meet
      the eligibility criteria are randomised and will enter a 12 month treatment period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III multi-centre, randomised open label study performed in subjects followed
      in primary care who have a diagnosis of and receive regular treatment for COPD in a localised
      geographical region of the UK
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2012</start_date>
  <completion_date type="Actual">November 24, 2015</completion_date>
  <primary_completion_date type="Actual">November 24, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Annual Rate of Moderate or Severe COPD Exacerbations</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>Mean annual rate of moderate or severe COPD exacerbations during treatment were assessed. Moderate exacerbation: participant received exacerbation-related prescription of oral corticosteroids and/ or antibiotic (with/without National Health Service [NHS] contact) not requiring hospitalisation. Severe exacerbation: an exacerbation-related hospitalisation. Analysis method was Generalised Linear Model (GLM) assuming the negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable, adjusted for randomized treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in previous year and smoking status at baseline. Intent to treat (ITT) population: all randomised participants who received a prescription of study medication. Primary Efficacy Analysis Population: all ITT participants who had at least one moderate/severe exacerbation in the year prior to randomization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study</measure>
    <time_frame>Up to 58 weeks</time_frame>
    <description>Incidence of SAE of pneumonia was defined for each randomized treatment group as the proportion (number) of participants in that group who experienced at least one SAE of pneumonia in the Pneumonia Adverse Event of Special Interest subgroup during the treatment period (from start date of exposure to stop date of exposure + 28 days). Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2. Serious Adverse Events of pneumonia are defined by the Pneumonia Special Interest Group, which for SAEs of pneumonia collected for these subjects includes the following preferred terms: Pneumonia, Pneumonia aspiration, Aspergillus infection, Empyema, Pneumonia streptococcal, Pneumonitis, Pulmonary tuberculosis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Number of Serious Adverse Events of Pneumonia During the Study</measure>
    <time_frame>Up to 58 weeks</time_frame>
    <description>The mean number of SAE of pneumonia over the treatment period (from first date of exposure to last date of exposure + 28 days was calculated. Analysis was performed using a negative binomial regression model with covariates of randomised treatment and with logarithm of time on treatment as an offset variable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the First Serious Adverse Event of Pneumonia Occuring in a Year</measure>
    <time_frame>Up to 52 weeks</time_frame>
    <description>The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Analyses included those on-treatment SAEs of pneumonia that had an onset over the first 364 days of exposure, as defined. Participants who did not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to end date of exposure + 28 days were considered censored. Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>A COPD-related secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an accident &amp; emergency (A&amp;E) contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. Inpatient admissions recorded at two hospitals on the same day, this was counted as a single (inpatient admission) secondary care contact. COPD-related contacts were identified using predefined lists of ICD-10 codes, specialty descriptions and diagnosis codes recorded in the patients electronic health record (EHR). GLM assuming the negative binomial distribution with log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>A COPD-related primary care contact was defined as a primary care contact on a given calendar date with either a nurse, general physician (GP) or other healthcare professional that were considered as COPD-related, if the most prominent signs and symptoms the participant was presenting were as a direct result of the participant's COPD, as per Readcodes recorded in the patients electronic health record (EHR). The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Secondary Care Contacts Expressed Using Least Square Mean</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>A secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an A&amp;E contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. In the situation where inpatient admissions were recorded at two hospitals on the same day, this was counted as a single secondary care contact. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomization stratification, number of moderate/severe COPD exacerbations in the previous year to randomization and smoking status at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of All Primary Care Contacts Expressed Using Least Square Mean</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>A primary care contact was defined as contact with a either a nurse, general practitioner, or other healthcare professional. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to an Event of Discontinuation of Initial Therapy Occurring in a Year</measure>
    <time_frame>Up to 364 days</time_frame>
    <description>Initial therapy was defined as the treatment that the subject was randomised to at randomisation. Discontinuation of initial therapy was defined as any modification of initial therapy. These included stepping up, stepping down or switching to another class/class combination, or withdrawal from the study. Switching within the same drug class did not count unless participant switched from FF/VI to a different ICS/LABA. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of discontinuation of initial therapy was measured from the date of randomisation (i.e., exposure start date) to the date of discontinuation of initial therapy to which the participant was randomized, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without discontinuing the initial therapy (censored). Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to the Addition of a Further COPD Controller Medication Occurring in a Year</measure>
    <time_frame>Up to 364 days</time_frame>
    <description>The date of an event for addition of a further COPD controller medication was defined as the exposure start date of the first modified treatment medication that included a new COPD maintenance therapy of a new class of drug (to the initial therapy) during the study treatment period, as collected on the investigational product page of the eCRF. Participants who did not add any COPD controller medication during the study were censored at the end of the treatment period (Day 364). This was equivalent to stepping up, defined as the addition of at least one new class of drug. The probability of an event was measured from the date of randomisation (i.e., treatment initiation) to the date of a change event. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate/Severe Exacerbations Occurring in a Year</measure>
    <time_frame>Up to 364 days</time_frame>
    <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of a first moderate / severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first moderate or severe COPD exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any moderate or severe exacerbations (censored). Participants who completed the study without a moderate or severe COPD exacerbation and analyses of time to first moderate/severe exacerbation were censored at Day 364. Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year</measure>
    <time_frame>Up to 364 days</time_frame>
    <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first moderate / severe exacerbation on initial therapy was measured from the date of randomisation (i.e., exposure start date) to the onset date of first moderate or severe COPD exacerbation, or to the date of discontinuation of initial therapy (analysis was censored at date of discontinuation of initial therapy) for participants who completed the study without any moderate or severe exacerbations on initial therapy. Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Severe Exacerbations Occurring in a Year</measure>
    <time_frame>Up to 364 days</time_frame>
    <description>The date of an event for severe exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe exacerbation were censored. The analysis method was a Cox proportional hazards model adjusted for randomized treatment.
The probability of first severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first severe exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any severe exacerbations (censored). At Day 364, all participants who have not experienced a severe exacerbation are considered censored, regardless of whether their on-treatment phase continues beyond day 364, including those who withdrew early. Number of participants with event is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Fatal Serious Adverse Events of Pneumonia</measure>
    <time_frame>Upto 58 weeks</time_frame>
    <description>All SAEs included in the AE subgroup of special interest of &quot;pneumonia&quot; were considered as an SAE of pneumonias. A fatal SAE was defined as a SAE with outcome of fatal for study participant. The number of participants with fatal SAEs of pneumonia was assessed over 14 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Non-serious Adverse Drug Reactions (ADR)</measure>
    <time_frame>Up to 54 weeks</time_frame>
    <description>The number of participants with non-serious ADRs was assessed for up to 54 weeks. An ADR is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. A non-serious ADR included one of the following: exacerbation of chronic or intermittent pre-existing condition; signs, symptoms, or the clinical sequelae of a suspected interaction; signs, symptoms, or new conditions detected or diagnosed after study treatment administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events</measure>
    <time_frame>Up to 56 weeks</time_frame>
    <description>SAEs assessed included medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a significant medical event in the investigator's judgment, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. SAEs were includes if the onset date was on or after the treatment start date and on or before the treatment stop date. However, the window for an SAE of pneumonia was longer and included 28 days post study treatment stop date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Drug Reactions</measure>
    <time_frame>Upto 12 months</time_frame>
    <description>A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2802</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>FF/VI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily via a Novel Dry Powder Inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Existing Maintenance Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Existing Maintenance Therapy:
Long acting bronchodilator therapy alone
ICS alone or in combination with a long acting bronchodilator
Triple maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF/VI</intervention_name>
    <description>FF/VI</description>
    <arm_group_label>FF/VI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Existing Maintenance Therapy</intervention_name>
    <description>Existing Maintenance Therapy:
Long acting bronchodilator therapy alone
ICS alone or in combination with a long acting bronchodilator
Triple maintenance therapy</description>
    <arm_group_label>Existing Maintenance Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects eligible for enrolment in the study must meet all of the following criteria:

          1. Type of subject: Subjects with documented GP diagnosis of COPD, and currently
             receiving maintenance therapy

          2. Informed consent: Subjects must be able to provide informed consent, have their
             consent signed and dated. Subjects must be able to complete the electronic subject
             questionnaires or allow a proxy to do so on their behalf.

          3. Gender and Age: Male or female subjects aged ≥40 years of age at Visit 1 A female is
             eligible to enter and participate in the study if she is of: Non-child bearing
             potential (i.e. physiologically incapable of becoming pregnant, including any female
             who is post-menopausal or surgically sterile). Surgically sterile females are defined
             as those with a documented hysterectomy and/or bilateral oophorectomy or tubal
             ligation. Post-menopausal females are defined as being amenorrhoeic for greater than 1
             year with an appropriate clinical profile, e.g. age appropriate, history of vasomotor
             symptoms. However in questionable cases, a blood sample with FSH &gt; 40MIU/ml and
             estradiol &lt;40pg/ml (&lt;140 pmol/L) is confirmatory. Or child bearing potential has a
             negative urine pregnancy test at Visit 2, and agrees to one of the highly effective
             and acceptable contraceptive methods used consistently and correctly (i.e. in
             accordance with the approved product label and the instructions of the physician for
             the duration of the study - Visit 2 to the end of the study).

          4. Subjects with Exacerbation History

          5. Current COPD Maintenance Therapy

        Exclusion Criteria:

        Subjects meeting any of the following criteria must not be enrolled in the study:

          1. Subjects with any life threatening condition (e.g. low probability (in the opinion of
             the GP/Investigator) of 12 month survival due to severity of COPD or co-morbid
             condition) at the point of entry into the study.

          2. Other diseases/abnormalities: Subjects with historical or current evidence of
             uncontrolled or clinically significant disease. Significant is defined as any disease
             that, in the opinion of the GP/ Investigator, would put the safety of the subject at
             risk through participation, or which would affect the efficacy or safety analysis if
             the disease/condition exacerbated during the study.

          3. Subjects with unstable COPD, defined as the occurrence of the following in the 2 weeks
             prior to Visit 2:

             - Acute worsening of COPD that is managed by the subject with corticosteroids or
             antibiotics or that requires treatment prescribed by a physician.

          4. Chronic user of oral corticosteroids: Subjects who, in the opinion of the
             GP/Investigator, are considered to be a chronic user of oral corticosteroids for
             respiratory or other indications (if unsure discuss with the medical monitor prior to
             screening)

          5. Drug/food allergy: Subjects with a history of hypersensitivity to any of the study
             medications (e.g., beta-agonists, corticosteroid) or components of the inhalation
             powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of
             severe milk protein allergy that, in the opinion of the GP/ Investigator,
             contraindicates the subject's participation will also be excluded.

          6. Investigational Medications: A subject must not have used any investigational drug
             treatment within 30 days prior to Visit 2 or within five half-lives (t½) of the prior
             investigational study (whichever is the longer of the two).

          7. Subjects who plan to move away from the geographical area where the study is being
             conducted during the study period and/or if subjects have not consented to their
             medical records being part of the electronic medical records database that is
             operational in the Salford area.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Cheshire</state>
        <zip>WA14 2NW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Cheshire</state>
        <zip>WA14 5ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Cheshire</state>
        <zip>WA14 5GR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Cheshire</state>
        <zip>WA14 5NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Cheshire</state>
        <zip>WA14 5PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bowdon</city>
        <state>Cheshire</state>
        <zip>WA14 3BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheadle Hulme</city>
        <state>Cheshire</state>
        <zip>SK8 5EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheadle</city>
        <state>Cheshire</state>
        <zip>SK8 6LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edgeley</city>
        <state>Cheshire</state>
        <zip>SK3 9LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gatley</city>
        <state>Cheshire</state>
        <zip>SK84NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heald Green</city>
        <state>Cheshire</state>
        <zip>SK8 3QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 2RH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 2UP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 4BR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sale</city>
        <state>Cheshire</state>
        <zip>M33 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <state>Cheshire</state>
        <zip>SK3 9NX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timperley</city>
        <state>Cheshire</state>
        <zip>WA15 7DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timperley</city>
        <state>Cheshire</state>
        <zip>WA15 7UN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Greater Manchester</state>
        <zip>WA14 2DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Altrincham</city>
        <state>Greater Manchester</state>
        <zip>WA15 6PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broadway, Davyhulme</city>
        <state>Greater Manchester</state>
        <zip>M41 7WJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <state>Greater Manchester</state>
        <zip>M44 5LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam</city>
        <state>Greater Manchester</state>
        <zip>M44 5LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 1EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 2DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 2RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 4SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M20 6WF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M22 4DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M22 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M22 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M22 5RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M22 9UE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M23 1JP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M23 1JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M23 9AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M27 9LB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M32 0DF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M32 0PA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M32 0RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 2TB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 3HF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 4WB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 5JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 5PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 7SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M33 7XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 0SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 0TZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 5AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 7FN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 7WJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M41 8AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>WA15 6BP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>WA15 7UN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newall Green</city>
        <state>Greater Manchester</state>
        <zip>M23 2SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northenden</city>
        <state>Greater Manchester</state>
        <zip>M22 4DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northern Moor</city>
        <state>Greater Manchester</state>
        <zip>M23 0BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pendlebury, Manchester</city>
        <state>Greater Manchester</state>
        <zip>M27 8HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pendlebury</city>
        <state>Greater Manchester</state>
        <zip>M27 8HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <state>Greater Manchester</state>
        <zip>M7 4TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 5PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 6ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M6 7HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <state>Greater Manchester</state>
        <zip>M7 1RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stretford</city>
        <state>Greater Manchester</state>
        <zip>M32 9BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timperley</city>
        <state>Greater Manchester</state>
        <zip>WA15 6PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Withington</city>
        <state>Greater Manchester</state>
        <zip>M20 1EY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe</city>
        <state>Greater Manchester</state>
        <zip>M22 0EP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe</city>
        <state>Greater Manchester</state>
        <zip>M22 5RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe</city>
        <state>Greater Manchester</state>
        <zip>M22 5RX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cadishead, Manchester</city>
        <zip>M44 5DD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cheadle</city>
        <zip>SK8 5BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0EJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0LS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 0TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 7JW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 8AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 8JA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 8QD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles, Manchester</city>
        <zip>M30 9PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eccles</city>
        <zip>M30 0TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ellenbrook, Manchester</city>
        <zip>M28 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <zip>M44 5LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <zip>M44 6AJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <zip>M44 6BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <zip>M44 6FE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Manchester</city>
        <zip>M44 6FN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Salford</city>
        <zip>M44 6DP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Irlam, Salford</city>
        <zip>M44 6ZS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M28 0AY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M28 0BA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M38 9GH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M38 9GR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M38 9LQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M38 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Hulton, Manchester</city>
        <zip>M38 9WX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M22 4HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M22 4QN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M23 1JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M28 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M32 8AQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M32 9PA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M33 3JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M33 4DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M33 7XZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 5BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 8GY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 8TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 9FD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 9NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M41 9SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Manchester</city>
        <zip>M7 4PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pendlebury, Manchester</city>
        <zip>M27 6EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M3 6AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M3 6BY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M5 3TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M5 4QU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M5 5HJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M5 5JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5FX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5JA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5WN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 7GU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 7HL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 8HA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 8LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M6 8NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 1QE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 1RD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 1UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 3SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 4AE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford, Manchester</city>
        <zip>M7 4AS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M5 3PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M5 4BS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 3PH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 5FX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 5JG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 5PP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M6 6ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M7 3SE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M7 4LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M7 4NX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salford</city>
        <zip>M7 4UF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <zip>SK2 7EY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <zip>SK3 9AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <zip>SK8 3JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <zip>SK8 3QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockport</city>
        <zip>SK8 5LL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton, Manchester</city>
        <zip>M27 0EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton, Manchester</city>
        <zip>M27 0NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton, Manchester</city>
        <zip>M27 4AF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton, Manchester</city>
        <zip>M27 4BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton</city>
        <zip>M27 4BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Swinton</city>
        <zip>M27 8HP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <zip>M28 3AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <zip>M28 3BT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <zip>M28 3DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <zip>M28 3EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <zip>M28 3ZD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Walkden, Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worsley, Manchester</city>
        <zip>M28 1FB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worsley, Manchester</city>
        <zip>M28 1LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worsley, Manchester</city>
        <zip>M28 3AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wythenshawe</city>
        <zip>M22 0LA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2012</study_first_posted>
  <results_first_submitted>September 5, 2016</results_first_submitted>
  <results_first_submitted_qc>January 13, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 7, 2017</results_first_posted>
  <last_update_submitted>May 3, 2017</last_update_submitted>
  <last_update_submitted_qc>May 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Exacerbation</keyword>
  <keyword>Adult</keyword>
  <keyword>COPD</keyword>
  <keyword>Respiratory</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>115151</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a multicentre, randomized, stratified, open-label study to evaluate the effectiveness and safety of fluticasone fuorate (FF)/vilanterol (VI) in participants followed in primary care who had a diagnosis of and received regular treatment for Chronic Obstructive Pulmonary Disease (COPD).</recruitment_details>
      <pre_assignment_details>Participants (par.) were randomized 1:1 to receive 1 inhalation of FF/VI 100 microgram (mcg)/25 mcg once daily (QD) or continued their existing maintenance therapy for 12 months. 2802 par. were randomized (3 par. randomized to the FF/VI arm did not receive study medication). A total of 2799 par. comprised the Intent to Treat (ITT) Population.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Usual Care</title>
          <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
        </group>
        <group group_id="P2">
          <title>Fluticasone Furoate (FF)/Vilanterol (VI) 100 mcg/25 mcg</title>
          <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1403"/>
                <participants group_id="P2" count="1396"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1309"/>
                <participants group_id="P2" count="1291"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="94"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-defined stopping criteria</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Usual Care</title>
          <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
        </group>
        <group group_id="B2">
          <title>FF/VI 100 mcg/25 mcg</title>
          <description>Participants were prescribed one inhalation of fluticasone furoate/vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1403"/>
            <count group_id="B2" value="1396"/>
            <count group_id="B3" value="2799"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.7" spread="9.93"/>
                    <measurement group_id="B2" value="66.6" spread="9.90"/>
                    <measurement group_id="B3" value="66.7" spread="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="671"/>
                    <measurement group_id="B2" value="698"/>
                    <measurement group_id="B3" value="1369"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="732"/>
                    <measurement group_id="B2" value="698"/>
                    <measurement group_id="B3" value="1430"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American/African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-Central/South Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian-South East Asian Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-Arabic/North African Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White-White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1387"/>
                    <measurement group_id="B2" value="1376"/>
                    <measurement group_id="B3" value="2763"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed Race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Annual Rate of Moderate or Severe COPD Exacerbations</title>
        <description>Mean annual rate of moderate or severe COPD exacerbations during treatment were assessed. Moderate exacerbation: participant received exacerbation-related prescription of oral corticosteroids and/ or antibiotic (with/without National Health Service [NHS] contact) not requiring hospitalisation. Severe exacerbation: an exacerbation-related hospitalisation. Analysis method was Generalised Linear Model (GLM) assuming the negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable, adjusted for randomized treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in previous year and smoking status at baseline. Intent to treat (ITT) population: all randomised participants who received a prescription of study medication. Primary Efficacy Analysis Population: all ITT participants who had at least one moderate/severe exacerbation in the year prior to randomization</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>Primary Efficacy Analysis Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Existing Maintenance Therapy:
Long acting bronchodilator therapy alone
ICS alone or in combination with a long acting bronchodilator
Triple maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Annual Rate of Moderate or Severe COPD Exacerbations</title>
          <description>Mean annual rate of moderate or severe COPD exacerbations during treatment were assessed. Moderate exacerbation: participant received exacerbation-related prescription of oral corticosteroids and/ or antibiotic (with/without National Health Service [NHS] contact) not requiring hospitalisation. Severe exacerbation: an exacerbation-related hospitalisation. Analysis method was Generalised Linear Model (GLM) assuming the negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable, adjusted for randomized treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in previous year and smoking status at baseline. Intent to treat (ITT) population: all randomised participants who received a prescription of study medication. Primary Efficacy Analysis Population: all ITT participants who had at least one moderate/severe exacerbation in the year prior to randomization</description>
          <population>Primary Efficacy Analysis Population.</population>
          <units>Exacerbations per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1134"/>
                <count group_id="O2" value="1135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" lower_limit="1.80" upper_limit="2.01"/>
                    <measurement group_id="O2" value="1.74" lower_limit="1.65" upper_limit="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.025</p_value>
            <method>Generalized Linear Model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study</title>
        <description>Incidence of SAE of pneumonia was defined for each randomized treatment group as the proportion (number) of participants in that group who experienced at least one SAE of pneumonia in the Pneumonia Adverse Event of Special Interest subgroup during the treatment period (from start date of exposure to stop date of exposure + 28 days). Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2. Serious Adverse Events of pneumonia are defined by the Pneumonia Special Interest Group, which for SAEs of pneumonia collected for these subjects includes the following preferred terms: Pneumonia, Pneumonia aspiration, Aspergillus infection, Empyema, Pneumonia streptococcal, Pneumonitis, Pulmonary tuberculosis.</description>
        <time_frame>Up to 58 weeks</time_frame>
        <population>The Intent-to-Treat (ITT) Population: Defined as all participants who were randomised and received at least one prescription of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study</title>
          <description>Incidence of SAE of pneumonia was defined for each randomized treatment group as the proportion (number) of participants in that group who experienced at least one SAE of pneumonia in the Pneumonia Adverse Event of Special Interest subgroup during the treatment period (from start date of exposure to stop date of exposure + 28 days). Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2. Serious Adverse Events of pneumonia are defined by the Pneumonia Special Interest Group, which for SAEs of pneumonia collected for these subjects includes the following preferred terms: Pneumonia, Pneumonia aspiration, Aspergillus infection, Empyema, Pneumonia streptococcal, Pneumonitis, Pulmonary tuberculosis.</description>
          <population>The Intent-to-Treat (ITT) Population: Defined as all participants who were randomised and received at least one prescription of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority is demonstrated if the upper limit of the two-sided 95% confidence interval for the incidence ratio is less than 2.</non_inferiority_desc>
            <param_type>Incidence ratio</param_type>
            <param_value>1.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9</ci_lower_limit>
            <ci_upper_limit>1.5</ci_upper_limit>
            <estimate_desc>Calculated as % of participants who had at least one SAE of pneumonia in the FF/VI group divided by the % of participants who had at least one SAE of pneumonia in the Usual Care group</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Number of Serious Adverse Events of Pneumonia During the Study</title>
        <description>The mean number of SAE of pneumonia over the treatment period (from first date of exposure to last date of exposure + 28 days was calculated. Analysis was performed using a negative binomial regression model with covariates of randomised treatment and with logarithm of time on treatment as an offset variable.</description>
        <time_frame>Up to 58 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Number of Serious Adverse Events of Pneumonia During the Study</title>
          <description>The mean number of SAE of pneumonia over the treatment period (from first date of exposure to last date of exposure + 28 days was calculated. Analysis was performed using a negative binomial regression model with covariates of randomised treatment and with logarithm of time on treatment as an offset variable.</description>
          <population>ITT Population.</population>
          <units>Mean Number of SAE</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" lower_limit="0.06" upper_limit="0.09"/>
                    <measurement group_id="O2" value="0.08" lower_limit="0.06" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.632</p_value>
            <method>Generalized linear model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the First Serious Adverse Event of Pneumonia Occuring in a Year</title>
        <description>The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Analyses included those on-treatment SAEs of pneumonia that had an onset over the first 364 days of exposure, as defined. Participants who did not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to end date of exposure + 28 days were considered censored. Number of participants with event is presented.</description>
        <time_frame>Up to 52 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the First Serious Adverse Event of Pneumonia Occuring in a Year</title>
          <description>The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Analyses included those on-treatment SAEs of pneumonia that had an onset over the first 364 days of exposure, as defined. Participants who did not have an SAE of pneumonia during the first 364 days of the treatment period (start date of exposure to end date of exposure + 28 days were considered censored. Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.439</p_value>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.83</ci_lower_limit>
            <ci_upper_limit>1.52</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean</title>
        <description>A COPD-related secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an accident &amp; emergency (A&amp;E) contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. Inpatient admissions recorded at two hospitals on the same day, this was counted as a single (inpatient admission) secondary care contact. COPD-related contacts were identified using predefined lists of ICD-10 codes, specialty descriptions and diagnosis codes recorded in the patients electronic health record (EHR). GLM assuming the negative binomial distribution with log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>ExParticipants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD-related Secondary Care Contacts Expressed as Least Square Mean</title>
          <description>A COPD-related secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an accident &amp; emergency (A&amp;E) contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. Inpatient admissions recorded at two hospitals on the same day, this was counted as a single (inpatient admission) secondary care contact. COPD-related contacts were identified using predefined lists of ICD-10 codes, specialty descriptions and diagnosis codes recorded in the patients electronic health record (EHR). GLM assuming the negative binomial distribution with log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
          <population>ITT Population.</population>
          <units>Contacts per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" lower_limit="1.30" upper_limit="1.67"/>
                    <measurement group_id="O2" value="1.57" lower_limit="1.39" upper_limit="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.488</p_value>
            <method>Generalized linear model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean</title>
        <description>A COPD-related primary care contact was defined as a primary care contact on a given calendar date with either a nurse, general physician (GP) or other healthcare professional that were considered as COPD-related, if the most prominent signs and symptoms the participant was presenting were as a direct result of the participant's COPD, as per Readcodes recorded in the patients electronic health record (EHR). The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of COPD-related Primary Care Contacts Expressed Using Least Square Mean</title>
          <description>A COPD-related primary care contact was defined as a primary care contact on a given calendar date with either a nurse, general physician (GP) or other healthcare professional that were considered as COPD-related, if the most prominent signs and symptoms the participant was presenting were as a direct result of the participant's COPD, as per Readcodes recorded in the patients electronic health record (EHR). The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
          <population>ITT Population.</population>
          <units>Contacts per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" lower_limit="2.34" upper_limit="2.58"/>
                    <measurement group_id="O2" value="2.42" lower_limit="2.30" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.622</p_value>
            <method>Generalized linear model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.92</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Secondary Care Contacts Expressed Using Least Square Mean</title>
        <description>A secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an A&amp;E contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. In the situation where inpatient admissions were recorded at two hospitals on the same day, this was counted as a single secondary care contact. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomization stratification, number of moderate/severe COPD exacerbations in the previous year to randomization and smoking status at baseline.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Secondary Care Contacts Expressed Using Least Square Mean</title>
          <description>A secondary care contact was defined as an inpatient admission or a specialist outpatient visit or an A&amp;E contact. A participant with an A&amp;E contact and subsequent inpatient admission was considered to have had two healthcare contacts. In the situation where inpatient admissions were recorded at two hospitals on the same day, this was counted as a single secondary care contact. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomization stratification, number of moderate/severe COPD exacerbations in the previous year to randomization and smoking status at baseline.</description>
          <population>ITT Population.</population>
          <units>Contacts per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.36" lower_limit="8.74" upper_limit="10.02"/>
                    <measurement group_id="O2" value="9.81" lower_limit="9.17" upper_limit="10.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.336</p_value>
            <method>Generalized Linear Model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.95</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of All Primary Care Contacts Expressed Using Least Square Mean</title>
        <description>A primary care contact was defined as contact with a either a nurse, general practitioner, or other healthcare professional. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>ITT Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Primary Care Contacts Expressed Using Least Square Mean</title>
          <description>A primary care contact was defined as contact with a either a nurse, general practitioner, or other healthcare professional. The analysis method was General Linear Model assuming an underlying negative binomial distribution with a log-link function and logarithm of time on treatment as an offset variable and adjusted for randomised treatment, baseline COPD maintenance therapy per randomisation stratification, number of moderate/severe COPD exacerbations in the previous year to randomisation and smoking status at baseline.</description>
          <population>ITT Population.</population>
          <units>Contacts per participant per year</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.88" lower_limit="18.06" upper_limit="19.74"/>
                    <measurement group_id="O2" value="21.20" lower_limit="20.27" upper_limit="22.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Generalized Linear Model</method>
            <param_type>Adjusted treatment ratio</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.05</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to an Event of Discontinuation of Initial Therapy Occurring in a Year</title>
        <description>Initial therapy was defined as the treatment that the subject was randomised to at randomisation. Discontinuation of initial therapy was defined as any modification of initial therapy. These included stepping up, stepping down or switching to another class/class combination, or withdrawal from the study. Switching within the same drug class did not count unless participant switched from FF/VI to a different ICS/LABA. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of discontinuation of initial therapy was measured from the date of randomisation (i.e., exposure start date) to the date of discontinuation of initial therapy to which the participant was randomized, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without discontinuing the initial therapy (censored). Number of participants with event is presented.</description>
        <time_frame>Up to 364 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to an Event of Discontinuation of Initial Therapy Occurring in a Year</title>
          <description>Initial therapy was defined as the treatment that the subject was randomised to at randomisation. Discontinuation of initial therapy was defined as any modification of initial therapy. These included stepping up, stepping down or switching to another class/class combination, or withdrawal from the study. Switching within the same drug class did not count unless participant switched from FF/VI to a different ICS/LABA. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of discontinuation of initial therapy was measured from the date of randomisation (i.e., exposure start date) to the date of discontinuation of initial therapy to which the participant was randomized, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without discontinuing the initial therapy (censored). Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219"/>
                    <measurement group_id="O2" value="374"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.60</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with FF/VI compared with Usual Care.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to the Addition of a Further COPD Controller Medication Occurring in a Year</title>
        <description>The date of an event for addition of a further COPD controller medication was defined as the exposure start date of the first modified treatment medication that included a new COPD maintenance therapy of a new class of drug (to the initial therapy) during the study treatment period, as collected on the investigational product page of the eCRF. Participants who did not add any COPD controller medication during the study were censored at the end of the treatment period (Day 364). This was equivalent to stepping up, defined as the addition of at least one new class of drug. The probability of an event was measured from the date of randomisation (i.e., treatment initiation) to the date of a change event. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Number of participants with event is presented.</description>
        <time_frame>Up to 364 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate/vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to the Addition of a Further COPD Controller Medication Occurring in a Year</title>
          <description>The date of an event for addition of a further COPD controller medication was defined as the exposure start date of the first modified treatment medication that included a new COPD maintenance therapy of a new class of drug (to the initial therapy) during the study treatment period, as collected on the investigational product page of the eCRF. Participants who did not add any COPD controller medication during the study were censored at the end of the treatment period (Day 364). This was equivalent to stepping up, defined as the addition of at least one new class of drug. The probability of an event was measured from the date of randomisation (i.e., treatment initiation) to the date of a change event. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cox proprotional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.37</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with FF/VI compared with Usual Care</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate/Severe Exacerbations Occurring in a Year</title>
        <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of a first moderate / severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first moderate or severe COPD exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any moderate or severe exacerbations (censored). Participants who completed the study without a moderate or severe COPD exacerbation and analyses of time to first moderate/severe exacerbation were censored at Day 364. Number of participants with event is presented.</description>
        <time_frame>Up to 364 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate/vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate/Severe Exacerbations Occurring in a Year</title>
          <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of a first moderate / severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first moderate or severe COPD exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any moderate or severe exacerbations (censored). Participants who completed the study without a moderate or severe COPD exacerbation and analyses of time to first moderate/severe exacerbation were censored at Day 364. Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="977"/>
                    <measurement group_id="O2" value="947"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.111</p_value>
            <method>Cox porportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.93</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
            <estimate_desc>A hazard ratio &lt;1 indicates a lower risk with FF/VI compared with Usual Care</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year</title>
        <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first moderate / severe exacerbation on initial therapy was measured from the date of randomisation (i.e., exposure start date) to the onset date of first moderate or severe COPD exacerbation, or to the date of discontinuation of initial therapy (analysis was censored at date of discontinuation of initial therapy) for participants who completed the study without any moderate or severe exacerbations on initial therapy. Number of participants with event is presented.</description>
        <time_frame>Up to 364 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate/vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate/Severe Exacerbations on Initial Therapy Occurring in a Year</title>
          <description>The date of an event for moderate / severe COPD exacerbation was defined as the exacerbation onset date. The analysis method was a Cox proportional hazards model adjusted for randomized treatment. The probability of first moderate / severe exacerbation on initial therapy was measured from the date of randomisation (i.e., exposure start date) to the onset date of first moderate or severe COPD exacerbation, or to the date of discontinuation of initial therapy (analysis was censored at date of discontinuation of initial therapy) for participants who completed the study without any moderate or severe exacerbations on initial therapy. Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="943"/>
                    <measurement group_id="O2" value="852"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.081</p_value>
            <method>Cox porportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Severe Exacerbations Occurring in a Year</title>
        <description>The date of an event for severe exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe exacerbation were censored. The analysis method was a Cox proportional hazards model adjusted for randomized treatment.
The probability of first severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first severe exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any severe exacerbations (censored). At Day 364, all participants who have not experienced a severe exacerbation are considered censored, regardless of whether their on-treatment phase continues beyond day 364, including those who withdrew early. Number of participants with event is presented.</description>
        <time_frame>Up to 364 days</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Severe Exacerbations Occurring in a Year</title>
          <description>The date of an event for severe exacerbation was defined as the exacerbation onset date. Participants who completed the study without a severe exacerbation were censored. The analysis method was a Cox proportional hazards model adjusted for randomized treatment.
The probability of first severe exacerbation was measured from the date of randomisation (i.e., treatment initiation) to the onset date of first severe exacerbation, as recorded on eCRF, or date of treatment termination (Visit 6 or early withdrawal visit) for participants who completed the study without any severe exacerbations (censored). At Day 364, all participants who have not experienced a severe exacerbation are considered censored, regardless of whether their on-treatment phase continues beyond day 364, including those who withdrew early. Number of participants with event is presented.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.075</p_value>
            <method>Cox proportional hazards model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Fatal Serious Adverse Events of Pneumonia</title>
        <description>All SAEs included in the AE subgroup of special interest of “pneumonia” were considered as an SAE of pneumonias. A fatal SAE was defined as a SAE with outcome of fatal for study participant. The number of participants with fatal SAEs of pneumonia was assessed over 14 months.</description>
        <time_frame>Upto 58 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal Serious Adverse Events of Pneumonia</title>
          <description>All SAEs included in the AE subgroup of special interest of “pneumonia” were considered as an SAE of pneumonias. A fatal SAE was defined as a SAE with outcome of fatal for study participant. The number of participants with fatal SAEs of pneumonia was assessed over 14 months.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Non-serious Adverse Drug Reactions (ADR)</title>
        <description>The number of participants with non-serious ADRs was assessed for up to 54 weeks. An ADR is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. A non-serious ADR included one of the following: exacerbation of chronic or intermittent pre-existing condition; signs, symptoms, or the clinical sequelae of a suspected interaction; signs, symptoms, or new conditions detected or diagnosed after study treatment administration.</description>
        <time_frame>Up to 54 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate/vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-serious Adverse Drug Reactions (ADR)</title>
          <description>The number of participants with non-serious ADRs was assessed for up to 54 weeks. An ADR is any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, for which there is a reasonable possibility that the untoward occurrence is causally related to the medicinal product. A non-serious ADR included one of the following: exacerbation of chronic or intermittent pre-existing condition; signs, symptoms, or the clinical sequelae of a suspected interaction; signs, symptoms, or new conditions detected or diagnosed after study treatment administration.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events</title>
        <description>SAEs assessed included medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a significant medical event in the investigator's judgment, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. SAEs were includes if the onset date was on or after the treatment start date and on or before the treatment stop date. However, the window for an SAE of pneumonia was longer and included 28 days post study treatment stop date.</description>
        <time_frame>Up to 56 weeks</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events</title>
          <description>SAEs assessed included medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a significant medical event in the investigator's judgment, or is an event of possible drug-induced liver injury with hyperbilirubinaemia. SAEs were includes if the onset date was on or after the treatment start date and on or before the treatment stop date. However, the window for an SAE of pneumonia was longer and included 28 days post study treatment stop date.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="383"/>
                    <measurement group_id="O2" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Drug Reactions</title>
        <description>A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
        <time_frame>Upto 12 months</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Usual Care</title>
            <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
          </group>
          <group group_id="O2">
            <title>FF/VI 100 mcg/25 mcg</title>
            <description>Participants were prescribed one inhalation of fluticasone furoate /vilanterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Drug Reactions</title>
          <description>A serious adverse drug reactions (SADR) is any untoward medical occurrence suspected to be medicinal product-related that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1403"/>
                <count group_id="O2" value="1396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs; from Visit 1) and non-serious adverse drug reactions (from Visit 2) were collected from study medication start until the end of treatment (up to Visit 6 or withdrawal, ie, approximately 54 weeks)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Usual Care</title>
          <description>Participants continued their existing maintenance therapy that included one of the following: an inhaled corticosteroid (ICS) alone or Long Acting Beta Agonist (LABA) alone or Long Acting Muscarinic Antagonist (LAMA) alone or combination of any two (ICS+LABA/ ICS+LAMA/ LABA+LAMA) or triple therapy (ICS+LABA+LAMA) at the appropriate dosing schedule, for 12 months</description>
        </group>
        <group group_id="E2">
          <title>FF/VI 100 mcg/25 mcg</title>
          <description>Participants were prescribed one inhalation of fluticasone fuorate /vilaneterol (FF/VI) 100 mcg/25 mcg via dry powder inhaler (DPI) once daily in the morning for 12 months in lieu of existing maintenance therapy. Participants on previous triple therapy received LAMA therapy additionally.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="383" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="404" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Microcytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Normochromic normocytic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pernicious anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Acute left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac ventricular thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diastolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Trifascicular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Deafness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Barrett’s oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dyskinesia oesophageal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastric dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal hypomotility</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intestinal ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Obstruction gastric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pancreatic insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypothermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Multi-organ failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Stent-graft endoleak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Unintentional medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vascular stent occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Alcoholic liver disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Autoimmune hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Jaundice cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Allergic granulomatous angiitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="89" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airway disease</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Abdominal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Biliary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Neutropenic sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Arthritis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aspergillus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Endophthalmitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haematoma infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Herpes zoster meningoencephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Mycetoma mycotic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pelvic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peritonitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Varicella zoster virus infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Viral labyrinthitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Brachial plexus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cardiac valve rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Contrast media reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumothorax traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Radiation mucositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Splenic rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Stress fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Transfusion reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Urethral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Blood electrolytes abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Prostatic specific antigen increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hyperosmolar hyperglycaemic state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypophagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Muscle necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Soft tissue swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Laryngeal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of lung</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bowen’s disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carcinoma in situ of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid body tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Gastrointestinal tract adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Glioblastoma multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Glottis carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung carcinoma cell type unspecified recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage 0</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Mantle cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Prostate cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Prostatic adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Refractory anaemia with an excess of blasts</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ureteral neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ureteric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cerebrovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>VIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vocal cord paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Brain mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid sinus syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Cervical myelopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dementia with Lewy bodies</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Drug withdrawal convulsions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Meningism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Radiculitis brachial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Unresponsive to stimuli</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>VIIth nerve paralysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Vascular dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Delirium tremens</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Self-injurious ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Calculus ureteric</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Renal mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sterile pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pickwickian syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Stridor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchial secretion retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Sputum retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Miliaria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Carotid endarterectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Aortic thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Blood pressure inadequately controlled</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Extremity necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Femoral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peripheral artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1396"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA version 18.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <description>In this study, only information regarding non- serious adverse drug reactions (ADRs) and serious adverse events (SAEs) were detected, documented and reported.</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="1403"/>
                <counts group_id="E2" subjects_affected="56" subjects_at_risk="1396"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

